VERACHEM, LLC

Metalloenzyme binding affinity prediction with VM2

VERACHEM, LLC is a company in national institute of general medical sciences based in GERMANTOWN, MD, founded in 2000.

Profile

Project summary: It is estimated that 40 to 50% of known enzymes can be characterized as metalloenzymes,
while currently only 7% of FDA-approved drugs in the United States target this class of protein. This is despite
the fact that there are many dozens of already identified metalloenzyme targets involved in virtually every
therapeutic area, including anti-inflammatory, antibiotics, antivirals, anticancer drugs, and more. This is in large
part because the already very difficult drug design requirement to maintain/increase the potency of an initial
ligand (drug-like molecule) while improving/maintaining its target selectivity and pharmacokinetic properties,
is made even harder by the complicated and often non-intuitive nature of metal-ligand and metal-protein
interactions. Accurate molecular modeling predictions of metalloenzyme-ligand binding affinities, then, would
be highly impactful in pharmaceutical industry drug research and development programs, because they would
allow R&D scientists to carry out computational experiments drastically reducing the number of expensive and
time-consuming bench experiments required to overcome the difficult metalloenzyme inhibitor design
challenges they face. However, currently available molecular modeling approaches are unable to make
predictions reliable enough to do this. Docking and scoring methods are able to determine, in many cases, t

VERACHEM, LLC is positioned in national institute of general medical sciences, a segment that rewards a clear, focused offering.

The company is recorded as being based in GERMANTOWN, MD.

Its current recorded stage is SBIR/STTR.

Recorded headcount: c_00001_00010 employees.

It has disclosed roughly $915K in funding.

Website: www.verachem.com